Table 2 Comparison of the regression of neovascularization and plus disease between studied groups during week 1 to week 24 after the treatment
Time | Outcome | Group | P value | |
|---|---|---|---|---|
IVB plus laser therapy, n (%) | Laser therapy alone, n (%) | |||
Week 1 | Neovascularization | 20 (95%) | 12 (55%) | 0.001 |
Plus Disease | 20 (95%) | 7 (32%) |  < 0.001 | |
Week 2 | Neovascularization | 20 (95%) | 16 (73%) | 0.036 |
Plus Disease | 20 (95%) | 12 (55%) | 0.001 | |
Week 3 | Neovascularization | 21 (100%) | 20 (91%) | 0.49 |
Plus Disease | 21 (100%) | 20 (91%) | 0.49 | |
Week 4 | Neovascularization | 21 (100%) | 21 (95%) | 0.243 |
Plus Disease | 21 (100%) | 21 (95%) | 0.243 | |
Week 24 | Neovascularization | 21 (100%) | 22 (100%) | Â |
Plus Disease | 21 (100%) | 22 (100%) | Â | |